StreetInsider.com News Articles

Form SCHEDULE 13G/A ClearPoint Neuro, Inc. Filed by: MAK CAPITAL ONE LLC

Wed, 12 Aug 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260812/26914143.html

Form SCHEDULE 13G/A ClearPoint Neuro, Inc. Filed by: MAK CAPITAL ONE LLC

Wed, 12 Aug 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260812/26914143.html

Form SCHEDULE 13G/A ClearPoint Neuro, Inc. Filed by: BIGGER CAPITAL FUND L P

Tue, 04 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260804/26866706.html

Form SCHEDULE 13G/A ClearPoint Neuro, Inc. Filed by: BIGGER CAPITAL FUND L P

Tue, 04 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260804/26866706.html

Clearpoint Neuro Inc. (CLPT) PT Lowered to $22 at Stifel, Buy Rating Maintained

Tue, 04 Aug 2026 09:59:17 -0400

(Updated - August 4, 2026 9:59 AM EDT)

Stifel analyst Tom Stephan lowered the price target on Clearpoint Neuro Inc. (NASDAQ: CLPT) to $22.00 (from $25.00) while maintaining a Buy rating.

The analyst commented, "The optics of CLPT’s 2Q26 print were not ideal: revenue of $10.9M missed our $12.9M, representing y/y organic growth of -HSD%; 2Q26 EBIT was below our estimate, as opex was a bit heavy; and 2026 revenue guidance was lowered by 7% at the midpoint from $54M to $50M.The reduced guidance is due to a shift in the company’s priorities—and this is a function of several key developments in

Clearpoint Neuro Inc. (CLPT) PT Lowered to $22 at Stifel, Buy Rating Maintained

Tue, 04 Aug 2026 09:59:17 -0400

(Updated - August 4, 2026 9:59 AM EDT)

Stifel analyst Tom Stephan lowered the price target on Clearpoint Neuro Inc. (NASDAQ: CLPT) to $22.00 (from $25.00) while maintaining a Buy rating.

Form 10-Q ClearPoint Neuro, Inc. For: Jun 30

Mon, 03 Aug 2026 17:18:00 -0400

si-local-file:///var/storage/secattach/20260803/26859346.html

Form 10-Q ClearPoint Neuro, Inc. For: Jun 30

Mon, 03 Aug 2026 17:18:00 -0400

si-local-file:///var/storage/secattach/20260803/26859346.html

ClearPoint Neuro, Inc. (CLPT) Misses Q2 EPS by 9c

Mon, 03 Aug 2026 16:39:29 -0400

ClearPoint Neuro, Inc. (NASDAQ: CLPT) reported Q2 EPS of ($0.38), $0.09 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $10.9 million versus the consensus estimate of $12.73 million.

For earnings history and earnings-related data on ClearPoint Neuro, Inc. (CLPT) click here.

Form 8-K ClearPoint Neuro, Inc. For: Aug 03

Mon, 03 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260803/26857756.html

Form 8-K ClearPoint Neuro, Inc. For: Aug 03

Mon, 03 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260803/26857756.html

ClearPoint Neuro Reports Second Quarter 2026 Results

Mon, 03 Aug 2026 16:05:00 -0400

Positive BioPharma Partner Regulatory Progress and Early Success in Focused Ultrasound Technology Platform Expansion

SOLANA BEACH, CA / ACCESS Newswire / August 3, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its second quarter ended June 30, 2026.

Second Quarter 2026 Highlights

Reported second quarter revenue of $10.9 million, representing 18% overall growth, including the recently acquired IRRAflow Portfolio; Biologics and Drug Delivery Revenue declined 15% in the quarter, primarily due to a

ClearPoint Neuro Reports Second Quarter 2026 Results

Mon, 03 Aug 2026 16:05:00 -0400

Positive BioPharma Partner Regulatory Progress and Early Success in Focused Ultrasound Technology Platform Expansion

Second Quarter 2026 Highlights

Reported second quarter revenue of $10.9 million, representing 18% overall growth, including the recently acquired IRRAflow Portfolio; Biologics and Drug Delivery Revenue declined 15% in the quarter, primarily due to a

ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel

Fri, 31 Jul 2026 16:05:00 -0400

RMAT Designation Supports an Expedited FDA Development and Review Pathway for Aspen's Investigational Autologous Cell Replacement Therapy for Parkinson's Disease.

SOLANA BEACH, CA / ACCESS Newswire / July 31, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulated its partner Aspen Neuroscience, Inc. on receiving Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for sasineprocel (ANPD001), Aspen's investigational autologous dopaminergic neuron cell replacement therapy for Parkinson's disease.

Highlights

The FDA has

ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel

Fri, 31 Jul 2026 16:05:00 -0400

RMAT Designation Supports an Expedited FDA Development and Review Pathway for Aspen's Investigational Autologous Cell Replacement Therapy for Parkinson's Disease.

Highlights

The FDA has

Form SCHEDULE 13G/A ClearPoint Neuro, Inc. Filed by: BlackRock, Inc.

Mon, 27 Jul 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260727/26820014.html

Form SCHEDULE 13G/A ClearPoint Neuro, Inc. Filed by: BlackRock, Inc.

Mon, 27 Jul 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260727/26820014.html

ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026

Tue, 21 Jul 2026 16:05:00 -0400

SOLANA BEACH, CA / ACCESS Newswire / July 21, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2026 second quarter on Monday, August 3^rd, after the market close.

Investors and analysts are invited to listen to the live broadcast review of the Company's 2026 second quarter on Monday, August 3^rd at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here.

ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026

Tue, 21 Jul 2026 16:05:00 -0400

Form 4 ClearPoint Neuro, Inc. For: Jul 01 Filed by: FLETCHER R JOHN

Mon, 06 Jul 2026 20:05:00 -0400

si-local-file:///var/storage/secattach/20260706/26737116.html

Form 4 ClearPoint Neuro, Inc. For: Jul 01 Filed by: FLETCHER R JOHN

Mon, 06 Jul 2026 20:05:00 -0400

si-local-file:///var/storage/secattach/20260706/26737116.html

Form 4 ClearPoint Neuro, Inc. For: Jul 01 Filed by: Richards Timothy T.

Mon, 06 Jul 2026 20:05:00 -0400

si-local-file:///var/storage/secattach/20260706/26737117.html

Form 4 ClearPoint Neuro, Inc. For: Jul 01 Filed by: Richards Timothy T.

Mon, 06 Jul 2026 20:05:00 -0400

si-local-file:///var/storage/secattach/20260706/26737117.html

Form 4 ClearPoint Neuro, Inc. For: Jun 30 Filed by: BURNETT JOSEPH

Thu, 02 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260702/26727554.html

Form 4 ClearPoint Neuro, Inc. For: Jun 30 Filed by: BURNETT JOSEPH

Thu, 02 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260702/26727554.html